z-logo
open-access-imgOpen Access
Prevalence of severe chloroquine resistance associates the point mutation in pfcrt and pfmdrI gene in eastern India
Author(s) -
Santanu Kar Mahapatra,
Subhankari Prasad Chakraborty,
Sabyasachi Das,
AmiyaKumar Hati,
Somenath Roy
Publication year - 2011
Publication title -
asian pacific journal of tropical disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.208
H-Index - 33
ISSN - 2222-1808
DOI - 10.1016/s2222-1808(11)60062-5
Subject(s) - chloroquine , plasmodium falciparum , point mutation , biology , west bengal , malaria , polymerase chain reaction , mutation , genotype , drug resistance , virology , gene , traditional medicine , genetics , medicine , immunology , socioeconomics , sociology
Objective: To evaluate the molecular mechanism of chloroquine resistant Plasmodium\udfalciparum malaria in West Bengal, eastern part, India. Methods: Parasitic bloods were collected\udfrom patients in Kolkata and Purulia, in vitro drug susceptibility test were performed in those\ud179 isolates. Now parasitic DNA was isolated by phenol chloroform extraction method and then\udpolymerase chain reaction and restriction fragment length polymorphism analysis of different\udcodons of pfcrt gene (76) and the pfmdrI gene (86, 1246) were assessed. Results: The response of\ud179 patients to chloroquine was determined. The prevalence of both pfcrt K76T (68.72%) and pfmdrI\udN86Y (43.1%) mutation was found here. But most importantly severe in vitro chloroquine resistance\udhas been found (53.07%) here, with either double 76T + 86Y mutation or triple 76T + 86Y + 1246Y\udmutation. Conclusions: Our present findings implicate that due to enormous drug (chloroquine)\udpressure, double mutation with pfcrt 76T + pfmdrI 86Y and triple mutation with pfcrt 76T + pfmdrI\ud86Y + pfmdrI 1246Y was highly correlated (P = 0.001) with in vitro chloroquine resistance for the\udfirst time in eastern India

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here